18F-2-Deoxy-2-Fluoro-D-Glucose Positron Emission Tomography: Computed Tomography for Preoperative Staging in Gastric Cancer Patients

Overview

Journal J Gastric Cancer

Date 2012 Oct 25

PMID 23094230

Citations 8

Authors

Seok Hwa Youn

Kyung Won Seo

Sang Ho Lee

Yeon Myung Shin

Ki Young Yoon

Affiliations

Soon will be listed here.

Abstract

Purpose: The use of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography-computed tomography as a routine preoperative modality is increasing for gastric cancer despite controversy with its usefulness in preoperative staging. In this study we aimed to determine the usefulness of preoperative positron emission tomography-computed tomography scans for staging of gastric cancer.

Materials And Methods: We retrospectively analyzed 396 patients' positron emission tomography-computed tomography scans acquired for preoperative staging from January to December 2009.

Results: The sensitivity of positron emission tomography-computed tomography for detecting early gastric cancer was 20.7% and it was 74.2% for advanced gastric cancer. The size of the primary tumor was correlated with sensitivity, and there was a positive correlation between T stage and sensitivity. For regional lymph node metastasis, the sensitivity and specificity of the positron emission tomography-computed tomography were 30.7% and 94.7%, respectively. There was no correlation between T stage and maximum standardized uptake value or between tumor markers and maximum standardized uptake value. Fluorodeoxyglucose uptake was detected by positron emission tomography-computed tomography in 24 lesions other than the primary tumors. Among them, nine cases were found to be malignant, including double primary cancers and metastatic cancers. Only two cases were detected purely by positron emission tomography-computed tomography.

Conclusions: Positron emission tomography-computed tomography could be useful in detecting metastasis or another primary cancer for preoperative staging in gastric cancer patients, but not for T or N staging. More prospective studies are needed to determine whether positron emission tomography-computed tomography scans should be considered a routine preoperative imaging modality.

Citing Articles

Value of multi-slice spiral computed tomography in the diagnosis of metastatic lymph nodes and N-stage of gastric cancer.

Jiang M, Wang X, Shan X, Pan D, Jia Y, Ni E J Int Med Res. 2018; 47(1):281-292.

PMID: 30501533 PMC: 6384478. DOI: 10.1177/0300060518800611.

Comparison of DWI and F-FDG PET/CT for assessing preoperative N-staging in gastric cancer: evidence from a meta-analysis.

Luo M, Song H, Liu G, Lin Y, Luo L, Zhou X Oncotarget. 2017; 8(48):84473-84488.

PMID: 29137440 PMC: 5663612. DOI: 10.18632/oncotarget.21055.

Limitations in the use of 18F-FDG PET in the pre-operative staging of gastric cancer: A case series.

Fonocho E, Aydin N, Reddy S, Misra S Int J Surg Case Rep. 2017; 36:147-150.

PMID: 28582710 PMC: 5458643. DOI: 10.1016/j.ijscr.2017.05.026.

Predictive Role of the Number of 18F-FDG-Positive Lymph Nodes Detected by PET/CT for Pre-Treatment Evaluation of Locally Advanced Gastric Cancer.

Wang X, Wei Y, Xue Y, Lu P, Yu L, Shen B PLoS One. 2016; 11(12):e0166836.

PMID: 27936109 PMC: 5147842. DOI: 10.1371/journal.pone.0166836.

Incremental diagnostic utility of gastric distension FDG PET/CT.

Le Roux P, Duong C, Cabalag C, Parameswaran B, Callahan J, Hicks R Eur J Nucl Med Mol Imaging. 2015; 43(4):644-53.

PMID: 26487512 DOI: 10.1007/s00259-015-3211-6.

References

Kelley J, Duggan J . Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003; 56(1):1-9. DOI: 10.1016/s0895-4356(02)00534-6. View

Park M, Lee W, Lim H, Park K, Choi J, Kim B . Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdom Imaging. 2008; 34(4):441-7. DOI: 10.1007/s00261-008-9424-4. View

Yun M, Lim J, Noh S, Hyung W, Cheong J, Bong J . Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med. 2005; 46(10):1582-8. View

Vitola J, Delbeke D, Sandler M, Campbell M, Powers T, Wright J . Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996; 171(1):21-6. DOI: 10.1016/S0002-9610(99)80067-1. View

Kim J . Surgical results in gastric cancer. Semin Surg Oncol. 1999; 17(2):132-8. DOI: 10.1002/(sici)1098-2388(199909)17:2<132::aid-ssu8>3.0.co;2-e. View

Sarela A, Miner T, Karpeh M, Coit D, Jaques D, Brennan M . Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg. 2006; 243(2):189-95. PMC: 1448917. DOI: 10.1097/01.sla.0000197382.43208.a5. View

Kole A, Plukker J, Nieweg O, Vaalburg W . Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer. 1998; 78(4):521-7. PMC: 2063088. DOI: 10.1038/bjc.1998.526. View

Dassen A, Lips D, Hoekstra C, Pruijt J, Bosscha K . FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol. 2009; 35(5):449-55. DOI: 10.1016/j.ejso.2008.11.010. View

Kim E, Lee W, Choi D, Lee S, Choi J, Kim B . The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. Eur J Radiol. 2010; 79(2):183-8. DOI: 10.1016/j.ejrad.2010.02.005. View

10.

Ott K, Fink U, Becker K, Stahl A, Dittler H, Busch R . Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003; 21(24):4604-10. DOI: 10.1200/JCO.2003.06.574. View

11.

Marczell A, Rosen H, Hentschel E . Diagnosis and tactical approach to surgery for early gastric carcinoma: a retrospective analysis of the past 16 years in an Austrian general hospital. Gastroenterol Jpn. 1989; 24(6):732-6. DOI: 10.1007/BF02774176. View

12.

Lordick F, Ott K, Krause B, Weber W, Becker K, Stein H . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8(9):797-805. DOI: 10.1016/S1470-2045(07)70244-9. View

13.

Valk P, Pounds T, HOPKINS D, Haseman M, Hofer G, Greiss H . Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995; 60(6):1573-81; discussion 1581-2. DOI: 10.1016/0003-4975(95)00752-0. View

14.

Ohgami M, Otani Y, Kumai K, Kubota T, Kim Y, Kitajima M . Curative laparoscopic surgery for early gastric cancer: five years experience. World J Surg. 1999; 23(2):187-92; discussion 192-3. DOI: 10.1007/pl00013167. View

15.

HIKI Y, Shimao J, Yamao Y, Kobayashi N, Kuranami M, Kikuchi S . The concepts, procedures, and problems related in endoscopic laser therapy of early gastric cancer. A retrospective study on early gastric cancer. Surg Endosc. 1989; 3(1):1-6. DOI: 10.1007/BF00591306. View

16.

Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K . Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004; 28(3):247-53. DOI: 10.1007/s00268-003-7191-5. View

17.

Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S . Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006; 9(3):192-6. DOI: 10.1007/s10120-006-0374-7. View

18.

Kim S, Kang K, Lee J, Kim H, Chang H, Choi J . Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging. 2005; 33(2):148-55. DOI: 10.1007/s00259-005-1887-8. View

19.

Stahl A, Ott K, Weber W, Becker K, Link T, Siewert J . FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003; 30(2):288-95. DOI: 10.1007/s00259-002-1029-5. View

20.

Yeung H, Macapinlac H, Karpeh M, Finn R, Larson S . Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience. Clin Positron Imaging. 2003; 1(4):213-221. DOI: 10.1016/s1095-0397(98)00018-1. View